Logo Medical Science Monitor

Call: +1.631.470.9640
Closed: National Holiday

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

01 December 2005

The impact of rosiglitazone on heat tolerance in patients with Type 2 Diabetes.

Jerrold Petrofsky, Scott Lee, Maria Cuneo-Libarona

Med Sci Monit 2005; 11(12): CR562-569 :: ID: 438852

Abstract

Background: Diabetes is associated with reduced tolerance to heat. Theinsulin sensitizer rosiglitazone (RSG), administered for glycemic control, has a secondary effect inincreasing vascular endothelial function. The hypothesis to be tested was if administration of rosiglitazonewould increase heat tolerance in people with diabetes. Material/Methods: Thirty subjects with diabetesand thirty control subjects were examined. A subset of 21 subjects with diabetes had RSG administeredat 4 mg per day for a period of 1 year. At 2 weeks, 4 weeks, 3 months, 6 months, and 1 year post administration,measurements were taken to assess any potential impact of this drug on thermoregulation. Parameters measuredwere sweat rate, skin temperature, body core temperature, and skin blood flow. Results: Results of theseexperiments showed that subjects with diabetes at baseline had 1) sensory impairment, 2) sweat glandimpairment 3) high skin temperatures, 4) and low blood flow reduction during heat exposure, all leadingto higher core temperature compared to controls subjects. After administration of rosiglitazone for 1year significant improvements in thermoregulation were observed. Trends for improvement in thermoregulationwere observed close to that of age matched control subjects. Conclusions: Heat tolerance can be improvedin people with diabetes when taking the insulin sensitizer RSG for Glycemic control, probably due toincreased endothelial cell function.

Keywords: Body Temperature Regulation - drug effects, Diabetes Mellitus, Type 2 - physiopathology, Hot Temperature, Hypoglycemic Agents - pharmacology, Skin Temperature - drug effects, Thiazolidinediones - pharmacology

Add Comment 0 Comments

Editorial

01 May 2024 : Editorial  

Editorial: First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) – Lifileucel (Amtagvi)

Dinah V. Parums

DOI: 10.12659/MSM.944927

Med Sci Monit 2024; 30:e944927

In Press

Clinical Research  

Percutaneous Coronary Intervention as a Non-Surgical Treatment for Ischemic Mitral Regurgitation in Patient...

Med Sci Monit In Press; DOI: 10.12659/MSM.943122  

Clinical Research  

Maxillary Canine Impaction: Assessing the Influence of Maxillary Anatomy Using Cone Beam Computed Tomography

Med Sci Monit In Press; DOI: 10.12659/MSM.944306  

Clinical Research  

Optimal Duration of Cold and Heat Compression for Forearm Muscle Biomechanics in Mixed Martial Arts Athlete...

Med Sci Monit In Press; DOI: 10.12659/MSM.944149  

Clinical Research  

A Retrospective Study of the Presentation, Diagnosis, Management, and Outcomes of 27 Patients with Osteogen...

Med Sci Monit In Press; DOI: 10.12659/MSM.944364  

Most Viewed Current Articles

17 Jan 2024 : Review article  

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799

0:00

14 Dec 2022 : Clinical Research  

Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase Levels

DOI :10.12659/MSM.937990

Med Sci Monit 2022; 28:e937990

0:00

16 May 2023 : Clinical Research  

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387

0:00

01 Jan 2022 : Editorial  

Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...

DOI :10.12659/MSM.935952

Med Sci Monit 2022; 28:e935952

0:00

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750